Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: An analysis of the Swedish Lymphoma Registry

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift


Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent CD20+ lymphoma. Its scarcity has made clinical trials difficult and there is no consensus on first-line treatment. We conducted a population-based study of all patients diagnosed with NLPHL in Sweden between 2000 and 2014 (N = 158; 41 women and 117 men), focusing on clinical features, therapy and overall survival. The median female and male age was 59 and 44 years, respectively (P = 0·002). In early-stage disease, there was little mortality and no survival differences between therapies. In patients with advanced-stage disease, mortality was relatively high in patients who did not receive first-line rituximab but absent in those who did (10-year survival, 55% vs. 100%; P = 0·033); there were no imbalances of prognostic factors between those two groups. In advanced stages, first-line rituximab use increased markedly between 2000-2004 and 2005-2014 (7% vs. 67%; P < 0·00005), as did 10-year survival, 53% vs. 72% (multivariate P = 0·027). Although all patients were diagnosed in the 2000s, this is the longest-followed (and largest) population-based cohort. We report a hitherto unreported 15-year median age difference between sexes, increasing rituximab use and improved survival.


  • Daniel Molin
  • Johan Linderoth
  • Björn Engelbrekt Wahlin
Externa organisationer
  • Uppsala universitet, Historiska institutionen
  • Skåne University Hospital
  • Karolinska Institute
  • Karolinska University Hospital

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi


Sidor (från-till)449-456
TidskriftBritish Journal of Haematology
Tidigt onlinedatum2017 feb 24
StatusPublished - 2017
Peer review utfördJa
Externt publiceradJa